ALNYLAM PHARMACEUTICALS, INC. (ALNY) Return on equity 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
39.8%FY2025 · since FY2016: -44.6% → 39.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 39.8% | +454.4 pp |
| FY2024 | -414.6% | — |
| FY2021 | -145.0% | -60.5 pp |
| FY2020 | -84.5% | -22.9 pp |
| FY2019 | -61.6% | -3.1 pp |
| FY2018 | -58.5% | -30.7 pp |
| FY2017 | -27.8% | +16.8 pp |
| FY2016 | -44.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice